Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.
Epistemonikos ID: ed55dd3c7b09243a0ab25e8bbf0aa27931266615
First added on: Mar 31, 2022